Literature DB >> 25638392

Mitochondrial Diseases Part III: Therapeutic interventions in mouse models of OXPHOS deficiencies.

Susana Peralta1, Alessandra Torraco2, Luisa Iommarini3, Francisca Diaz4.   

Abstract

Mitochondrial defects are the cause of numerous disorders affecting the oxidative phosphorylation system (OXPHOS) in humans leading predominantly to neurological and muscular degeneration. The molecular origin, manifestations, and progression of mitochondrial diseases have a broad spectrum, which makes very challenging to find a globally effective therapy. The study of the molecular mechanisms underlying the mitochondrial dysfunction indicates that there is a wide range of pathways, enzymes and molecules that can be potentially targeted for therapeutic purposes. Therefore, focusing on the pathology of the disease is essential to design new treatments. In this review, we will summarize and discuss the different therapeutic interventions tested in some mouse models of mitochondrial diseases emphasizing the molecular mechanisms of action and their potential applications.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Mitochondria; Mitochondrial diseases; Mouse models; OXPHOS; Oxidative phosphorylation

Mesh:

Substances:

Year:  2015        PMID: 25638392      PMCID: PMC4516588          DOI: 10.1016/j.mito.2015.01.007

Source DB:  PubMed          Journal:  Mitochondrion        ISSN: 1567-7249            Impact factor:   4.160


  86 in total

Review 1.  Engineering the alternative oxidase gene to better understand and counteract mitochondrial defects: state of the art and perspectives.

Authors:  Riyad El-Khoury; Kia K Kemppainen; Eric Dufour; Marten Szibor; Howard T Jacobs; Pierre Rustin
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

2.  Molecular mechanisms underlying genotype-dependent responses to dietary restriction.

Authors:  Jennifer Schleit; Simon C Johnson; Christopher F Bennett; Marissa Simko; Natalie Trongtham; Anthony Castanza; Edward J Hsieh; Richard M Moller; Brian M Wasko; Joe R Delaney; George L Sutphin; Daniel Carr; Christopher J Murakami; Autumn Tocchi; Bo Xian; Weiyang Chen; Tao Yu; Sarani Goswami; Sean Higgins; Mollie Holmberg; Ki-Soo Jeong; Jin R Kim; Shannon Klum; Eric Liao; Michael S Lin; Winston Lo; Hillary Miller; Brady Olsen; Zhao J Peng; Tom Pollard; Prarthana Pradeep; Dillon Pruett; Dilreet Rai; Vanessa Ros; Minnie Singh; Benjamin L Spector; Helen Vander Wende; Elroy H An; Marissa Fletcher; Monika Jelic; Peter S Rabinovitch; Michael J MacCoss; Jing-Dong J Han; Brian K Kennedy; Matt Kaeberlein
Journal:  Aging Cell       Date:  2013-08-11       Impact factor: 9.304

3.  mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome.

Authors:  Simon C Johnson; Melana E Yanos; Ernst-Bernhard Kayser; Albert Quintana; Maya Sangesland; Anthony Castanza; Lauren Uhde; Jessica Hui; Valerie Z Wall; Arni Gagnidze; Kelly Oh; Brian M Wasko; Fresnida J Ramos; Richard D Palmiter; Peter S Rabinovitch; Philip G Morgan; Margaret M Sedensky; Matt Kaeberlein
Journal:  Science       Date:  2013-11-14       Impact factor: 47.728

4.  Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia.

Authors:  Morgane Perdomini; Brahim Belbellaa; Laurent Monassier; Laurence Reutenauer; Nadia Messaddeq; Nathalie Cartier; Ronald G Crystal; Patrick Aubourg; Hélène Puccio
Journal:  Nat Med       Date:  2014-04-06       Impact factor: 53.440

5.  Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3.

Authors:  Nahid A Khan; Mari Auranen; Ilse Paetau; Eija Pirinen; Liliya Euro; Saara Forsström; Lotta Pasila; Vidya Velagapudi; Christopher J Carroll; Johan Auwerx; Anu Suomalainen
Journal:  EMBO Mol Med       Date:  2014-06       Impact factor: 12.137

6.  Gene therapy using a liver-targeted AAV vector restores nucleoside and nucleotide homeostasis in a murine model of MNGIE.

Authors:  Javier Torres-Torronteras; Carlo Viscomi; Raquel Cabrera-Pérez; Yolanda Cámara; Ivano Di Meo; Jordi Barquinero; Alberto Auricchio; Giuseppe Pizzorno; Michio Hirano; Massimo Zeviani; Ramon Martí
Journal:  Mol Ther       Date:  2014-01-22       Impact factor: 11.454

7.  AAV-mediated liver-specific MPV17 expression restores mtDNA levels and prevents diet-induced liver failure.

Authors:  Emanuela Bottani; Carla Giordano; Gabriele Civiletto; Ivano Di Meo; Alberto Auricchio; Emilio Ciusani; Silvia Marchet; Costanza Lamperti; Giulia d'Amati; Carlo Viscomi; Massimo Zeviani
Journal:  Mol Ther       Date:  2013-07-03       Impact factor: 11.454

8.  Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle.

Authors:  Eija Pirinen; Carles Cantó; Young Suk Jo; Laia Morato; Hongbo Zhang; Keir J Menzies; Evan G Williams; Laurent Mouchiroud; Norman Moullan; Carolina Hagberg; Wei Li; Silvie Timmers; Ralph Imhof; Jef Verbeek; Aurora Pujol; Barbara van Loon; Carlo Viscomi; Massimo Zeviani; Patrick Schrauwen; Anthony A Sauve; Kristina Schoonjans; Johan Auwerx
Journal:  Cell Metab       Date:  2014-05-08       Impact factor: 27.287

9.  NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease.

Authors:  Raffaele Cerutti; Eija Pirinen; Costanza Lamperti; Silvia Marchet; Anthony A Sauve; Wei Li; Valerio Leoni; Eric A Schon; Françoise Dantzer; Johan Auwerx; Carlo Viscomi; Massimo Zeviani
Journal:  Cell Metab       Date:  2014-05-08       Impact factor: 27.287

10.  Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs.

Authors:  Sandra R Bacman; Siôn L Williams; Milena Pinto; Susana Peralta; Carlos T Moraes
Journal:  Nat Med       Date:  2013-08-04       Impact factor: 53.440

View more
  7 in total

1.  Sustained AMPK activation improves muscle function in a mitochondrial myopathy mouse model by promoting muscle fiber regeneration.

Authors:  Susana Peralta; Sofia Garcia; Han Yang Yin; Tania Arguello; Francisca Diaz; Carlos T Moraes
Journal:  Hum Mol Genet       Date:  2016-06-10       Impact factor: 6.150

Review 2.  Dysfunctional mitochondrial bioenergetics and the pathogenesis of hepatic disorders.

Authors:  Christopher Auger; Azhar Alhasawi; Manuraj Contavadoo; Vasu D Appanna
Journal:  Front Cell Dev Biol       Date:  2015-06-25

3.  Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation.

Authors:  Milena Pinto; Nadee Nissanka; Susana Peralta; Roberta Brambilla; Francisca Diaz; Carlos T Moraes
Journal:  Mol Neurodegener       Date:  2016-04-02       Impact factor: 14.195

Review 4.  Mitochondrial disorders in children: toward development of small-molecule treatment strategies.

Authors:  Werner Jh Koopman; Julien Beyrath; Cheuk-Wing Fung; Saskia Koene; Richard J Rodenburg; Peter Hgm Willems; Jan Am Smeitink
Journal:  EMBO Mol Med       Date:  2016-04-01       Impact factor: 12.137

Review 5.  The genetics and pathology of mitochondrial disease.

Authors:  Charlotte L Alston; Mariana C Rocha; Nichola Z Lax; Doug M Turnbull; Robert W Taylor
Journal:  J Pathol       Date:  2016-11-02       Impact factor: 7.996

Review 6.  Review: Central nervous system involvement in mitochondrial disease.

Authors:  N Z Lax; G S Gorman; D M Turnbull
Journal:  Neuropathol Appl Neurobiol       Date:  2016-07-07       Impact factor: 8.090

Review 7.  Role of Bioactive Compounds in the Regulation of Mitochondrial Dysfunctions in Brain and Age-Related Neurodegenerative Diseases.

Authors:  Khadidja Kessas; Zhor Chouari; Imen Ghzaiel; Amira Zarrouk; Mohamed Ksila; Taoufik Ghrairi; Adil El Midaoui; Gérard Lizard; Omar Kharoubi
Journal:  Cells       Date:  2022-01-13       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.